Future-Proof Your Clinical Research Career
The transition from R2 to R3 is not just an update; it is a fundamental shift in how clinical trials are designed and monitored. The industry is moving away from “tick-box compliance” toward Quality by Design (QbD).
This course is built for Principal Investigators, CRAs, Project Managers, and QA professionals who need to operationalize the 11 Principles of ICH-GCP E6(R3) immediately.
What You Will Master
- The R3 Delta: Navigate the new “fit-for-purpose” approach and the two-annex structure (Interventional vs. Non-traditional).
- Risk-Based Quality Management (RBQM): Learn to design a Quality Management Plan that identifies “Critical to Quality” factors before the trial starts.
- Digital Governance: Manage data integrity across wearables, eConsent, and decentralized platforms (DCTs).
- Vendor Oversight: Clearly define responsibilities between Sponsors, CROs, and IT vendors to prevent regulatory gaps.
Course Curriculum
Module 1: The Paradigm Shift
- Evolution of GCP: R2 vs. R3
- The 11 Core Principles & The Two-Annex Structure
- Implementing a Culture of Quality (QbD)
Module 2: RBQM in Action
- Identifying Critical to Quality (CtQ) Factors
- Risk Assessment Workshops & Tolerance Limits (QTLs)
- Risk Reporting under new guidelines
Module 3: Data Governance & Technology
- The Modern Data Lifecycle (Wearables, EHRs)
- Computerized Systems Validation (CSV) for AI/Agile systems
- Data Integrity 2.0 (ALCOA++ in decentralized trials)
Module 4: Roles & Oversight
- The Modern Investigator: Oversight of non-clinical staff
- Sponsor Oversight: Managing IT vendors and CROs
- Informed Consent: eConsent and dynamic models
Module 5: Advanced Operations
- Decentralized Clinical Trials (DCTs)
- Pragmatic & Adaptive Trial Designs
- The Digital TMF: Reconstruction of the trial
Certification & Recognition
Upon passing the final capstone assessment, you will be awarded the Certified ICH-GCP E6 (R3) Practitioner credential.
- Verifiable Digital Badge: Showcase your expertise on LinkedIn and professional portfolios.
- Continuous Relevance: Access to updates as the R3 guideline is finalized and amended.
- Leadership Signal: Prove to sponsors and employers that you are ready to manage complex, technology-driven trials.







Reviews
There are no reviews yet.